IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, reagent kits, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells and beads. IntelliCyts products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences.
Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet needs in phenotypic small molecule drug discovery, antibody discovery, in vitro toxicology as well as other high profile research areas. By combining the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, IntelliCyts HTFC Screening System enables suspension cell assays at speeds up to 40x faster than traditional flow cytometry. IntelliCyt has integrated HTFC with application-specific reagent kits and informatics software to address the growing market for high throughput cell based assays to provide earlier, more physiologically relevant results at lower cost.
Founder, President and CEO at Intellicyt
George Dunbar joined Arboretum Ventures in 2010 as a Venture Partner. George utilizes his extensive healthcare operating experience as the former CEO of a number of venture-backed healthcare companies to evaluate new investment opportunities in diagnostics, life science tools, and medical devices. George currently serves as the Executive Chairman of the Board of Directors at CerviLenz and serves on the boards of directors for KFx Medical and IntelliCyt Corporation.
Prior to joining Arboretum, George was the President, CEO, and Chairman of Aastrom Biosciences [NASDAQ: ASTM], a clinical development stage healthcare company based in Ann Arbor, Michigan. Prior to Aastrom, George worked with several national venture capital firms, serving as the CEO of early-stage life sciences companies, including Quantum Dot (acquired by Invitrogen) and Epic Therapeutics (acquired by Baxter Healthcare).
Prior to joining Village Ventures, Matt was Vice President of corporate development and finance at CyberCrop.com, Inc., where he was instrumental in the development of the company’s initial business plan and securing over $25 million in financing. Additionally, he was involved in setting the strategic direction of the company and securing strategic partners.
Prior to CyberCrop.com, Matt was a Vice President at Koch Ventures, Inc., where he led investments in companies such as VerticalNet, Inc. (NASDAQ: VERT), Universal Access, Inc., (NASDAQ: UAXS), and Energy Interactive (Acquired: ABB). Matt focuses on healthcare related investments, including healthcare IT, healthcare services, medical technology, and outsourced services for the pharmaceutical and biotech industries.
Matt graduated from the University of Kansas and now resides in Denver, Colorado.
Vice President Product Development at Intellicyt
Chief Commercial Officer at Intellicyt